Glaukos Corporation (GKOS)

Executive Summary / Key Takeaways

• Glaukos is pioneering the interventional glaucoma revolution, with iDose TR driving 30%+ U.S. growth by replacing decades of eye drop non-compliance with a sustained-release implant, addressing a 12-13 million patient opportunity that management believes will eventually exceed the 5 million annual cataract surgery market.

• The company is simultaneously executing a high-stakes product transition in corneal health, launching Epioxa as a $78,500 incision-free therapy while discontinuing Photrexa, establishing what could become the new standard of care for keratoconus.

• 2026 guidance of $600-620 million implies 20%+ growth, but this reflects an expected dip in Q2 corneal health as patients wait for Epioxa's permanent J-code, making execution on patient access and payer coverage the critical swing factor for the stock.

• While Glaukos maintains technological leadership in MIGS devices and sustained-release pharmaceuticals, five Medicare LCD restrictions and competitive trialing headwinds in international markets demonstrate that reimbursement and competitive dynamics remain material threats to the standalone stent business.

• Trading at 11.8x sales with no debt and $279 million in cash, the premium valuation reflects optimism about the massive addressable markets, but leaves little margin for error on Epioxa launch execution or iDose TR reimbursement expansion.

Setting the Scene: From Micro-Stents to Dropless Ophthalmic Platforms

Glaukos Corporation, founded in 1998 and headquartered in Aliso Viejo, California, has spent 27 years evolving from a single-product MIGS device company into a diversified ophthalmic therapy platform targeting glaucoma, corneal disorders, and retinal disease. This transformation positions Glaukos at the intersection of two massive market shifts: the move from pharmaceutical management to interventional procedures in glaucoma, and the replacement of invasive surgical therapies with incision-free drug delivery in corneal health.

The ophthalmic industry structure reveals the strategic importance of this positioning. Traditional glaucoma treatment relies on daily eye drops that suffer from 50%+ non-compliance rates, while invasive trabeculectomy surgery carries significant risks and recovery time. In corneal health, keratoconus affects approximately 90% of patients bilaterally, with up to 20% of untreated cases requiring corneal transplants, yet fewer than 1 in 5 diagnosed patients currently receive treatment due to the invasive nature of epithelium-removal procedures. Glaukos addresses these gaps with iDose TR, a sustained-release travoprost implant that eliminates daily drops for 2-3 years, and Epioxa, the first FDA-approved topical keratoconus therapy that preserves the corneal epithelium.

Competitively, Glaukos operates in a landscape dominated by giants like Alcon (ALC), Johnson & Johnson (JNJ), and Bausch + Lomb (BLCO). These players offer broad portfolios but lack Glaukos' focused interventional glaucoma expertise. Alcon's Hydrus Microstent and J&J's Baerveldt implant target similar patients but require more complex procedures, while Bausch + Lomb's ELIOS laser system represents an alternative approach. Glaukos' moat lies in its specialized micro-scale technology and first-mover advantage in sustained-release pharmaceuticals, enabling it to grow 32% in 2025 while its larger peers expand at single-digit rates.

Technology, Products, and Strategic Differentiation

iDose TR: Creating a New Therapeutic Category

iDose TR represents Glaukos' most significant technological and economic breakthrough. This intracameral implant continuously delivers travoprost inside the eye for extended periods, addressing the $1 billion annual cost of glaucoma medication non-compliance. The technology transforms a chronic daily management problem into a procedural solution performed in minutes, creating a new recurring revenue model tied to procedure volume rather than prescription refills.

The economic implications are profound. With a permanent J-code (J7355) established and temporary CPT codes for the procedural component, iDose TR generated $136 million in 2025 sales, accelerating from $31 million in Q2 to $45 million in Q4. Management expects 30% U.S. glaucoma growth in 2026 driven entirely by iDose TR, while the legacy stent business remains flat. This mix shift toward sustained-release pharmaceuticals improves pricing power and margins, as evidenced by the 78% underlying gross margin (excluding the Photrexa impairment) compared to traditional device margins.

The January 2026 FDA approval for unlimited re-administration removes a key limitation, allowing physicians to retreat patients as needed. While this is expected to be a more material contributor in 2027-2028, it eliminates a potential adoption barrier and extends the lifetime value of each patient. The Phase IIb/III iDose TREX program, showing 8.6-10.8 mmHg IOP reductions through three months, and the Phase IIIb iDose TRIO study with a new closed-chamber applicator, demonstrate a pipeline that can sustain growth beyond the current generation.

Epioxa: Transforming Corneal Health Through Incision-Free Therapy

Epioxa's FDA approval in October 2025 represents a strategic inflection point that forced Glaukos to take a $112.9 million impairment charge on Photrexa. This write-down signals management's conviction that Epioxa's superior patient experience—no epithelium removal, faster recovery—will rapidly obsolete the prior standard of care. The $78,500 wholesale acquisition cost is positioned as significantly lower than nearly all other rare disease drugs, enabling substantial investment in patient access and awareness.

The launch dynamics create near-term risk but long-term opportunity. Management anticipates a dip in Q2 2026 as patients wait for the permanent J-code expected by July 2026, followed by a strong exit in Q4 as treatment patterns normalize. This concentrates 2026 corneal health performance into the second half, making quarterly tracking critical for investors. The company has deployed O2n Systems covering nearly 50% of the U.S. population and engaged payers representing 50% of commercially covered lives, including 4 of the top 5 commercial payers, suggesting strong payer acceptance despite the price point.

The strategic rationale extends beyond immediate revenue. With only 10,000 patients treated annually with Photrexa (fewer than 20% of diagnosed unstable keratoconus patients) and 40% of confirmed cases delaying or declining therapy due to invasiveness, Epioxa addresses a massive untreated population. The planned 2026 launch of a keratoconus screening tool could further expand the addressable market by improving diagnosis rates.

iStent Family: Defending the MIGS Foundation

The iStent product line remains strategically important as the foundation of Glaukos' interventional glaucoma platform. The iStent infinite, cleared for standalone use or with cataract surgery, received EU MDR certification in June 2025, enabling launches in European markets where management expects high single-digit international growth in 2026. This provides geographic diversification and offsets competitive pressures in the U.S.

However, five Medicare LCDs implemented in Q4 2024 created turbulence by restricting the use of two MIGS devices in the same procedure, contributing to mid-single-digit declines in the U.S. stent business. CMS's proposed 2026 rules reducing physician fees for Category I CPT codes further pressures the traditional stent business. This reimbursement headwind explains why management expects the non-iDose business to be flat in 2026, concentrating growth in the iDose TR franchise.

Financial Performance & Segment Dynamics: Evidence of Strategy Execution

Revenue Growth Driven by iDose TR Momentum

2025 net sales of $507.4 million, up 32% year-over-year, provide evidence that the interventional glaucoma strategy is working. The composition reveals the underlying drivers: iDose TR grew from $31 million in Q2 to $45 million in Q4, while the iStent family plus iDose TR accounted for 83% of net sales. This concentration shows Glaukos is successfully transitioning from a device company to a procedural pharmaceutical platform, with higher-margin, recurring-revenue characteristics.

The quarterly progression shows adoption despite seasonal headwinds. Q1 2025 U.S. glaucoma net sales of $59.1 million (up 41% year-over-year) were driven by iDose TR, offsetting stent declines. Q4 2025's $45 million iDose TR performance represented broad-based growth across all MAC regions, with Medicare Advantage utilization increasing. This demonstrates that reimbursement is stabilizing and that the product is gaining traction beyond traditional Medicare fee-for-service.

Margin Structure and Path to Profitability

The 56% reported gross margin for 2025, down from 75% in 2024, is due to the $112.9 million Photrexa impairment. The underlying gross margin of approximately 77-78% reflects the strong economics of iDose TR and iStent products, supporting the thesis that a mix shift toward pharmaceuticals will drive margin expansion. Operating expenses grew 17% to $482.4 million in 2025, with management targeting mid-teens growth to $555-560 million in 2026 while still expecting operating leverage.

This expense growth reflects strategic investments in Epioxa launch infrastructure, patient access programs, and the Huntsville, Alabama R&D and manufacturing facility. The philosophy of balancing investments against revenues to drive toward cash flow breakeven suggests disciplined capital allocation, but the $80+ million multi-year capex commitment for Huntsville will pressure free cash flow near-term.

The accumulated deficit of $933.1 million as of December 31, 2025, reflects the heavy R&D investment required to build this platform, but the $278.8 million cash position with no debt provides runway. Operating cash flow improved from -$61.3 million in 2024 to -$14.8 million in 2025, demonstrating progress toward the goal of cash flow breakeven in 2026.

Segment Dynamics and Mix Shift Implications

The glaucoma franchise's dominance means the company's fate is tied to iDose TR's continued expansion. Management's guidance that U.S. glaucoma growth will be driven entirely by iDose TR with the non-iDose business flat implies that any slowdown in iDose adoption would require downward revision. The international glaucoma business, growing 18% in Q4 2025, provides some diversification, but competitive launch headwinds in major markets could pressure this growth in 2026.

Corneal health's 17% of sales and 8% growth in 2025 masks the underlying transition. The Q4 2025 impairment charge signals confidence in Epioxa's superiority, but the anticipated Q2 2026 dip creates earnings volatility. The franchise's importance extends beyond revenue, as it demonstrates Glaukos' ability to develop and commercialize bio-activated pharmaceuticals, a capability applicable to the retinal pipeline.

Outlook, Management Guidance, and Execution Risk

2026 Guidance: Ambitious but Achievable

Management's reaffirmed guidance of $600-620 million net sales for 2026 implies 20% growth at the midpoint, a deceleration from 2025's 32% but still robust. The key assumption is that iDose TR continues sequential growth throughout 2026, with U.S. glaucoma expanding 30% year-over-year. This requires iDose TR to overcome seasonality and maintain momentum despite the stent business remaining flat.

The guidance's composition reveals strategic priorities. Corneal health is expected to grow modestly year-over-year, with Q2 representing the transition period and Q4 showing the strongest results. This phasing concentrates execution risk into the first half of 2026, making Q2 and Q3 results critical indicators of Epioxa's success.

Reimbursement and Market Access Execution

The iDose TR reimbursement landscape remains a key variable. With professional fees formally published by only three of seven MACs (Noridian, Novitas, First Coast) as of Q4 2025, growth in these regions has outpaced others, demonstrating that fee establishment drives utilization. The remaining four MACs represent significant untapped opportunity, but also execution risk if fees are set too low to incentivize procedures.

For Epioxa, the miscellaneous J-code in Q1 2026 followed by a permanent J-code by July 2026 creates a warehousing effect where patients delay treatment. Management's deployment of O2n Systems to cover 50% of the U.S. population and engagement with payers covering 50% of commercial lives shows proactive infrastructure building, but the guidance acknowledges that patient pull-through may be slower than historical device launches.

Competitive and Macro Headwinds

International glaucoma guidance of high single-digit growth assumes that competitive product trialing headwinds in key markets will be offset by iStent infinite launches. This reflects management's realism about competitive pressure while betting that new product approvals can maintain growth. The EU MDR certification for iStent infinite, providing a broad label for all stages of open-angle glaucoma, is crucial for this offset strategy.

Macroeconomic conditions, including potential U.S. tariffs and interest rate impacts on surgery centers, represent background risk. However, Glaukos' U.S.-centric manufacturing and minimal exposure to Chinese imports limits direct tariff impact, while the elective nature of glaucoma procedures could face pressure if economic conditions deteriorate.

Risks and Asymmetries: What Could Break the Thesis

Epioxa Launch Execution Risk

The most material risk is Epioxa's commercial execution. Management acknowledges initial patient access will be gated by site of care network deployment and typical payer adoption headwinds, with a material dip in Q2 expected. If the O2n System deployment stalls, payer coverage decisions delay beyond July 2026, or patient education campaigns fail to drive diagnosis rates, the corneal health franchise could decline year-over-year.

The $78,500 WAC, while justified by management as competitive within rare disease ophthalmology, could face payer pushback if budget pressures intensify. The fact that management has not heard any formal or informal pushback to date is encouraging but not predictive, especially as more patients seek treatment and hit prior authorization barriers.

iDose TR Reimbursement and Competitive Pressure

While iDose TR currently uses Category III CPT codes unaffected by CMS's proposed physician fee reductions, any reclassification to Category I could reduce reimbursement levels, as occurred with surgical MIGS procedures. The five MAC LCDs that disrupted the stent business demonstrate how quickly reimbursement changes can impact volumes, and similar restrictions could target sustained-release pharmaceuticals if deemed cost-ineffective.

Competitive threats are intensifying. Alcon's Hydrus Microstent, Bausch + Lomb's ELIOS laser system, and AbbVie (ABBV) sustained-release pharmaceutical efforts could erode Glaukos' first-mover advantage. The expiration of Photrexa's orphan drug exclusivity in 2023 already enabled third-party development, and while Epioxa's technology is differentiated, competitors are investing heavily in adjacent solutions.

Manufacturing Concentration and Supply Chain

Glaukos' sole manufacturing location for iStent and iDose products in San Clemente, CA, and reliance on limited third-party suppliers create single-point-of-failure risk. Any disruption from natural disasters, quality issues, or supplier insolvency could halt production. The Huntsville facility, while mitigating long-term risk, won't be operational for several years and requires $80+ million in capital expenditures that will pressure free cash flow.

Profitability and Cash Flow Sustainability

Despite progress toward breakeven, Glaukos remains unprofitable with a -$187.7 million net loss in 2025 and -$54 million free cash flow. The company has accumulated a $933 million deficit since inception, and while the $279 million cash position provides runway, sustained losses could require dilutive equity financing if growth stalls. The mid-teens operating expense growth targeted for 2026 still outpaces revenue growth implied by guidance, delaying profitability.

Valuation Context: Premium Pricing for Transformational Growth

At $103.18 per share, Glaukos trades at a $5.99 billion market capitalization, or 11.8x trailing twelve months sales of $507 million. This premium to ophthalmic device peers—Alcon at 3.5x sales, Bausch + Lomb at 1.1x sales, and J&J at 6.2x sales—reflects the market's recognition of Glaukos' pharmaceutical-like growth profile and massive addressable markets.

The enterprise value of $5.82 billion (11.5x revenue) must be evaluated against the company's unique position. Unlike traditional device companies with single-digit growth, Glaukos is delivering 20%+ top-line expansion driven by iDose TR's 30% growth trajectory. The 78% underlying gross margin exceeds peers (Alcon 56%, Bausch + Lomb 60%, J&J 68%), supporting the thesis that sustained-release pharmaceuticals command premium pricing and manufacturing economics.

Balance sheet strength provides strategic flexibility. With no debt, a 4.7x current ratio, and $279 million in cash, Glaukos can fund the Epioxa launch, Huntsville facility construction, and pipeline development without near-term financing risk. This allows management to invest through the Epioxa transition period without compromising strategic initiatives.

However, the valuation leaves no room for execution missteps. The -18.9% operating margin and -37% profit margin reflect the heavy investment phase, but investors are pricing in rapid improvement. If iDose TR growth decelerates or Epioxa launch disappoints, the 11.8x sales multiple could compress toward peer levels. Conversely, successful execution that drives $600+ million 2026 revenue and demonstrates a path to profitability could justify current levels and provide upside as the company approaches Rule of 40 territory.

Conclusion: Execution at the Intersection of Revolution and Transition

Glaukos stands at a pivotal inflection point where its pioneering interventional glaucoma platform is scaling toward a multi-billion dollar opportunity while its corneal health franchise undergoes a high-risk, high-reward transformation. The central thesis hinges on two variables: iDose TR's ability to maintain 30%+ growth by capturing share from eye drops and competing MIGS devices, and Epioxa's capacity to rapidly replace Photrexa while expanding the keratoconus treatment market.

The company's technological moats—proprietary micro-scale stent platforms and first-mover sustained-release pharmaceuticals—provide durable competitive advantages that justify premium valuation. However, the concentration of growth in iDose TR and the anticipated Q2 2026 dip in corneal health create execution risk. Reimbursement stability, particularly the establishment of professional fees in remaining MAC regions and Epioxa's permanent J-code adoption, will be critical leading indicators.

For investors, the risk/reward is asymmetric: successful execution on both fronts could drive revenue toward $1 billion by 2028 with expanding margins, validating the current valuation and providing substantial upside. Conversely, any misstep on Epioxa patient access, iDose TR reimbursement, or competitive encroachment could compress the multiple toward peer levels. The strong balance sheet provides a cushion, but 2026 will be a year where quarterly progress on patient pull-through and market access will determine whether Glaukos emerges as a diversified ophthalmic leader or remains a niche device player with pharmaceutical aspirations.